Cargando…
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity
Treatment of cancer with poly (ADP-ribose) polymerase (PARP) inhibitors is currently limited to cells defective in the homologous recombination (HR) pathway. Identification of genetic targets that induce or mimic HR deficiencies will extend the clinical utility of PARP inhibitors. Here we perform a...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733792/ https://www.ncbi.nlm.nih.gov/pubmed/31508509 http://dx.doi.org/10.1038/s42003-019-0580-6 |